5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Glaxosmithkline Pharmaceuticals Ltd.

•
gsk-india.comBSE: 500660NSE: GLAXO
Market Cap₹ 48,893 Cr.
Current Price
High / Low₹ 3,121 / 2,088
Stock P/E46.1
Book Value₹ 148
Price to Book17.14
Dividend Yield1.97 %
ROCE65.8 %
ROE47.9 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 28.7% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 59.5%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.3%
  • Operating margins have improved to 31.0% from 25.5%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.09x)

CONS

  • Stock is trading at 17.1x its book value
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 5.4% over past five years
  • Growth is decelerating - 3Y profit CAGR (18.7%) trails the 5Y trend (28.7%)
  • Expensive relative to growth - PEG of 2.5

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 150NIFTY TOTAL MKTNIFTY 500
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.GLAXO2886.1545.7748893.121.97237.1815.69938.4416.5566.7931.49
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
7389538059118111,0009469668059741,023989924
597667587656582681656635554639655642648
Operating Profit141287218255229319290331251335368347276
OPM %19.14%30.06%27.02%28.03%28.29%31.89%30.66%34.24%31.16%34.37%35.95%35.10%29.89%
5428-13532363735394434323662
Interest0001000101111
Depreciation16181718161719151617201316
Profit before Tax17929765269248339306355279351378369338
Tax %26.93%27.31%30.13%28.15%26.90%26.58%25.39%26.70%26.52%27.28%26.65%25.51%25.05%
Net Profit13121645193182249229260205255277275253
7.7112.722.6911.2910.7214.4513.4915.3512.0814.9216.3616.2314.95

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,9032,8723,1293,2252,9203,2183,2163,4073,7233,7903,910
2,4832,3632,5222,5662,3232,4622,4172,5072,5542,4902,584
Operating Profit4205086066585987567999011,1691,3001,326
OPM %14.47%17.71%19.39%20.42%20.47%23.49%24.86%26.43%31.40%34.30%33.91%
11871106-247-6288101-20147145163
Interest00164222133
Depreciation2638498379686670676667
Profit before Tax5115426643224537738328091,2481,3761,436
Tax %34.11%35.01%35.91%65.88%36.75%51.31%27.35%27.73%26.38%26.48%26.13%
Net Profit3373524251102873776055859191,0121,060
EPS39.7620.7825.116.5021.1099.7935.8834.5154.2559.73—
Dividend Payout %75.45%84.22%79.65%615.73%177.27%404.87%89.65%92.72%99.54%95.43%—

COMPOUNDED SALES GROWTH

10 Years:
3%
5 Years:
5%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
10%
5 Years:
29%
3 Years:
19%

STOCK PRICE CAGR

10 Years:
7%
5 Years:
13%
3 Years:
25%
1 Year:
0%

RETURN ON EQUITY

10 Years:
25%
5 Years:
35%
3 Years:
43%
Last Year:
48%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2018

Sep 11

1:1

Bonus issue Inter alia, 1. Mr. Marc Jones, Non-Executive Director and Mr. Rajeshwar R. Bajaaj, Independent Director have ceased to be a Directors of the Company from close of the business hours on 24th July 2018. 2. Bonus Issue The Board considered, approved and recommended a bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8585169169169169169169169169
1,9441,9951,9731,6711,3282,5081,5851,6241,7952,087
43229221047217
Trade Payables276503403354448555419613704550
4,2385,0135,2308001,0281,2671,0179891,2901,317
Total Liabilities6,5467,5987,7783,0232,9954,5103,1953,4023,9604,141
253323430757386329329320283280
Capital Work in Progress5739231,003120133120141433
48482524243905438381,1431,416
425500486483523513438514463430
0000000222293273
Cash & Bank8821,2801,1551,0661,1582,4791,1511,0611,4011,355
4,3654,5254,679572891768714432364354
Total Assets6,5467,5987,7783,0232,9954,5103,1953,4023,9604,141

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
3906766217057609687587181,280881
Cash from Investing303-107-154-63408-42080515-37385
Cash from Financing-511-307-358-428-696-524-1,544-561-769-737
2561-1020307-124-25132474530

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
75.0075.0075.0075.0075.0075.0075.0075.0075.00
4.024.364.504.524.894.804.634.624.79
7.507.347.307.797.717.767.707.687.81
Government0.000.000.000.000.000.000.000.000.00
13.4813.3013.1912.6912.4112.4512.6612.7012.41

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-02
General Updates

2026-09-02 - GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General UpdatesCorrigendum to the Notice of Postal Ballot dated August 3, 2026

2026-09-02
Shareholders meeting

2026-09-02 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot

2026-09-02
Copy of Newspaper Publication

2026-09-02 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-19
General Updates

2026-08-19 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates

2026-08-14
Copy of Newspaper Publication

2026-08-14 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
Shareholders meeting

2026-08-13 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot

2026-08-06
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-06 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript

2026-08-06
Action(s) taken or orders passed

2026-08-06 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

2026-08-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording

News

Recent coverage and analyst commentary for GLAXO

Loading news…

🤖

AI Stock Analyst

Glaxosmithkline Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login